Integral Health Asset Management LLC Purchases New Position in Dyne Therapeutics, Inc. $DYN

Integral Health Asset Management LLC acquired a new stake in Dyne Therapeutics, Inc. (NASDAQ:DYN) in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 800,000 shares of the company’s stock, valued at approximately $10,120,000.

Other hedge funds also recently made changes to their positions in the company. AQR Capital Management LLC purchased a new stake in shares of Dyne Therapeutics in the 1st quarter valued at about $246,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in shares of Dyne Therapeutics by 5.4% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 56,466 shares of the company’s stock valued at $597,000 after purchasing an additional 2,886 shares during the period. Goldman Sachs Group Inc. grew its stake in Dyne Therapeutics by 58.2% during the 1st quarter. Goldman Sachs Group Inc. now owns 994,886 shares of the company’s stock worth $10,407,000 after buying an additional 366,183 shares during the last quarter. Caxton Associates LLP acquired a new position in Dyne Therapeutics during the first quarter worth approximately $157,000. Finally, Geode Capital Management LLC increased its position in Dyne Therapeutics by 15.2% during the second quarter. Geode Capital Management LLC now owns 2,253,670 shares of the company’s stock worth $21,458,000 after buying an additional 298,165 shares during the period. Hedge funds and other institutional investors own 96.68% of the company’s stock.

Insider Transactions at Dyne Therapeutics

In other news, Director Brian S. Posner acquired 3,000 shares of the business’s stock in a transaction on Friday, March 6th. The stock was bought at an average price of $15.06 per share, for a total transaction of $45,180.00. Following the transaction, the director owned 11,500 shares in the company, valued at $173,190. This represents a 35.29% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through the SEC website. Corporate insiders own 14.14% of the company’s stock.

Dyne Therapeutics Trading Down 0.8%

Shares of DYN stock opened at $17.92 on Friday. The company has a market capitalization of $2.96 billion, a P/E ratio of -5.06 and a beta of 1.34. The company has a current ratio of 22.25, a quick ratio of 22.25 and a debt-to-equity ratio of 0.15. The business’s 50 day moving average is $16.99 and its two-hundred day moving average is $17.26. Dyne Therapeutics, Inc. has a twelve month low of $6.36 and a twelve month high of $25.00.

Dyne Therapeutics (NASDAQ:DYN) last released its quarterly earnings results on Monday, March 2nd. The company reported ($0.76) EPS for the quarter, missing the consensus estimate of ($0.74) by ($0.02). Equities analysts forecast that Dyne Therapeutics, Inc. will post -3.44 EPS for the current year.

Wall Street Analyst Weigh In

DYN has been the subject of several research analyst reports. HC Wainwright decreased their price objective on Dyne Therapeutics from $60.00 to $50.00 and set a “buy” rating for the company in a report on Tuesday, March 3rd. Wall Street Zen downgraded shares of Dyne Therapeutics from a “hold” rating to a “sell” rating in a research report on Sunday, December 28th. Jefferies Financial Group reiterated a “buy” rating on shares of Dyne Therapeutics in a research note on Monday. Stifel Nicolaus raised their price objective on shares of Dyne Therapeutics from $36.00 to $39.00 and gave the stock a “buy” rating in a research report on Thursday, December 11th. Finally, TD Cowen restated a “buy” rating on shares of Dyne Therapeutics in a research note on Monday, December 8th. Three analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Dyne Therapeutics currently has an average rating of “Moderate Buy” and a consensus price target of $35.14.

Dyne Therapeutics Profile

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company’s proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne’s lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.